The American Society of Clinical Oncology (ASCO) recently reported major scientific advances in the following areas: new therapy options for hard-to-treat lung and pancreatic cancers; FDA drug approvals for women with advanced breast cancer that does not express the HER2 gene (the majority of breast cancers) and people with chronic lymphocytic leukemia (a cancer with few treatments); reducing recurrence of breast and skin cancers; personalized cancer medicine; reducing cancer risk; and improving access to care. The 2008 ASCO annual progress report, developed by an editorial board of leading cancer specialists, also includes two recommendations to policymakers to accelerate progress against cancer: increase cancer research funding and improve access to clinical trials.
For details about each research advancement, visit cancer.net
Comments temporarily disabled